Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
National Clinical Research Center for Geriatric Disorders, Beijing, 100053, China.
BMC Anesthesiol. 2020 Sep 7;20(1):229. doi: 10.1186/s12871-020-01145-0.
Hypotension following spinal anesthesia (SA) during cesarean delivery (CD) occurs commonly and is related with maternal and fetal complications. Norepinephrine infusion is increasingly used for prevention of post-SA hypotension; however, its effects as compared to the traditional phenylephrine infusion remain unclear. This study aimed to compare the effects of phenylephrine and norepinephrine administered as continuous infusion during elective CD on maternal hemodynamic parameters and maternal and fetal outcomes.
This prospective, single-center, randomized, controlled study included 238 consecutive term parturients who underwent CD from February 2019 to October 2019. They were randomized to receive continuous infusion of 0.25 μg/kg/min phenylephrine, 0.05 μg/kg/min norepinephrine, or placebo. Hemodynamic monitoring was performed at 10 time points using LiDCOrapid. We analyzed umbilical vein (UV), umbilical artery (UA), and peripheral vein (PV) blood gas indexes and recorded intraoperative complications.
In phenylephrine group, the systolic blood pressure (SBP) remain during the whole operation. Compared to the control group, phenylephrine, but not norepinephrine, significantly increased the systemic vascular resistance (SVR) to counteract the SA-induced vasodilatation, 3 min following norepinephrine/phenylephrine/LR administration (T4): 957.4 ± 590.3 vs 590.1 ± 273.7 (P < 0.000001); 5 min following norepinephrine/phenylephrine/LR administration (T5): 1104 ± 468.0 vs 789.4 ± 376.2 (P = 0.000002). at the time of incision (T6): 1084 ± 524.8 vs 825.2 ± 428.6 (P = 0.000188). Parturients in the phenylephrine group had significantly lower UV (1.91 ± 0.43) (P = 0.0003) and UA (2.05 ± 0.61) (P = 0.0038) lactate level compared to controls. Moreover, the UV pH value was higher in the phenylephrine than in the control group7.37 ± 0.03(P = 0.0013). Parturients had lower incidence of nausea, tachycardia, hypotension in phenylephrine group.
In this dataset, continuous phenylephrine infusion reduced the incidence of SA-induced hypotension, ameliorated SVR, while decreasing overall maternal complications. Phenylephrine infusions are considered the better choice during CD because of the significant benefit to the fetus.
Clinicaltrial.gov Registry, NCT03833895 , Registered on 1 February 2019.
剖宫产术中椎管内麻醉(SA)后发生低血压较为常见,与产妇和胎儿并发症有关。去甲肾上腺素输注越来越多地用于预防 SA 后低血压;然而,与传统的苯肾上腺素输注相比,其效果尚不清楚。本研究旨在比较在择期剖宫产中连续输注苯肾上腺素和去甲肾上腺素对产妇血流动力学参数以及产妇和胎儿结局的影响。
这是一项前瞻性、单中心、随机、对照研究,纳入了 2019 年 2 月至 2019 年 10 月期间接受剖宫产的 238 例足月产妇。他们被随机分为接受 0.25μg/kg/min 苯肾上腺素、0.05μg/kg/min 去甲肾上腺素或安慰剂的连续输注。使用 LiDCOrapid 在 10 个时间点进行血流动力学监测。我们分析了脐静脉(UV)、脐动脉(UA)和外周静脉(PV)血气指标,并记录了术中并发症。
在苯肾上腺素组,整个手术过程中的收缩压(SBP)保持不变。与对照组相比,苯肾上腺素而非去甲肾上腺素显著增加了全身血管阻力(SVR),以对抗 SA 引起的血管扩张,在去甲肾上腺素/苯肾上腺素/LR 给药后 3 分钟(T4):957.4±590.3 与 590.1±273.7(P<0.000001);去甲肾上腺素/苯肾上腺素/LR 给药后 5 分钟(T5):1104±468.0 与 789.4±376.2(P=0.000002)。在切开时(T6):1084±524.8 与 825.2±428.6(P=0.000188)。与对照组相比,苯肾上腺素组的 UV(1.91±0.43)(P=0.0003)和 UA(2.05±0.61)(P=0.0038)乳酸水平明显较低。此外,苯肾上腺素组的 UV pH 值高于对照组 7.37±0.03(P=0.0013)。苯肾上腺素组产妇恶心、心动过速、低血压的发生率较低。
在本数据集,连续苯肾上腺素输注可降低 SA 引起的低血压发生率,改善 SVR,同时降低产妇总体并发症发生率。苯肾上腺素输注被认为是剖宫产的更好选择,因为对胎儿有显著的益处。
Clinicaltrial.gov 注册,NCT03833895,于 2019 年 2 月 1 日注册。